Cancer
Malignant Prostate Neoplasm
CI-CAN-00005927Explore in graph →
Top-level1,377 active trials24 approved drugs58 evidence items
- NCIt
- C7378
- ICD-10
- C61
- DOID
- 10283
- Other
- 2 more codes
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00005927Explore in graph →
Clinical trials
5,979 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (730)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03442556 | Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency | terminated | Phase 2 | 18 | University of WashingtonOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT04631601 | Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC) | terminated | Phase 1 / Phase 2 | 55 | AmgenINDUSTRY | 6 | Aug 26, 2026 | clinicaltrials |
| NCT04019327 | A Study of the Drugs Talazoparib and Temozolomide in Prostate Cancer | terminated | Phase 1 / Phase 2 | 16 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT00126230 | Trial of Docetaxel-samarium in Patients With Hormone-refractory Advanced Prostate Cancer | terminated | Phase 2 | 55 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT02769962 | Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 45 | National Cancer Institute (NCI)NIH | 1 | Aug 13, 2026 | clinicaltrials |
| NCT03152786 | Propranolol Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery | terminated | Phase 2 | 46 | Wake Forest University Health SciencesOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT06022757 | Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19) | terminated | Phase 1 / Phase 2 | 12 | Evopoint Biosciences Inc.INDUSTRY | 1 | Jul 23, 2026 | clinicaltrials |
| NCT05689021 | CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations | terminated | Phase 2 | 8 | Mayo ClinicOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT04698564 | Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging | terminated | Phase 2 | 4 | University of Maryland, BaltimoreOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT05067777 | Massage for Prostate Cancer-Related Fatigue (mPROSTATE)(mPROSTATE) | terminated | Phase 2 | 28 | University of UtahOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT05597878 | Opioid-Free Pain Control Regimen Following Robotic Radical Prostatectomy | terminated | Phase 2 / Phase 3 | 58 | Wake Forest University Health SciencesOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT01885949 | Tivozanib + Enzalutamide in Adv Prostate Cancer | terminated | Phase 2 | 5 | Massachusetts General HospitalOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT00183937 | Study of Bortezomib and Docetaxel for Patients With Hormone Refractory Prostate Cancer | terminated | Phase 2 | 15 | University of Southern CaliforniaOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT03437941 | Study to Evaluate Exicorilant (CORT125281) in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer | terminated | Phase 1 / Phase 2 | 39 | Corcept TherapeuticsINDUSTRY | 2 | May 15, 2026 | clinicaltrials |
| NCT04716725 | 68Ga-PSMA-11 PET for the Diagnosis of Metastatic Castration Resistant Prostate Cancer | terminated | Phase 2 | 15 | Thomas HopeOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT04030559 | Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects | terminated | Phase 2 | 11 | University of California, DavisOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT04631744 | Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC) | terminated | Phase 2 | 4 | Weill Medical College of Cornell UniversityOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT06630325 | A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer | terminated | Phase 2 | 6 | OHSU Knight Cancer InstituteOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT05588609 | Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers | terminated | Phase 2 | 13 | Partner Therapeutics, Inc.INDUSTRY | 1 | Apr 27, 2026 | clinicaltrials |
| NCT04984343 | Randomized Trial of Five or Two MRI-Guided Adaptive Radiotherapy Treatments for Prostate Cancer(FORT) | terminated | Phase 2 | 33 | Weill Medical College of Cornell UniversityOTHER | 2 | Apr 23, 2026 | clinicaltrials |
| NCT02555189 | Enzalutamide With Ribociclib in Treating Patients With Metastatic Castrate-Resistant, Chemotherapy Naive Prostate Cancer That Retains Retinoblastoma Expression | terminated | Phase 1 / Phase 2 | 52 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT03869762 | Denosumab in Combination With Enzalutamide in Progressive Metastatic Castrate-resistant Prostate Cancer and Bone Metastases.(DICE) | terminated | Phase 2 | 7 | Cancer Trials IrelandNETWORK | 1 | Apr 13, 2026 | clinicaltrials |
| NCT03360721 | Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer | terminated | Phase 2 | 7 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT03652298 | Effects of a Neuroscience-based Technique on Cancer Patients Announced of a Palliative Disease Progression and Partners(NeuroPrevPTSD) | terminated | Phase 2 | 19 | Centre Oscar LambretOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT04179864 | A Study of Tazemetostat With Enzalutamide or Abiraterone/Prednisone in Participants With Advanced Prostate Cancer(CELLO-1) | terminated | Phase 1 / Phase 2 | 102 | Epizyme, Inc.INDUSTRY | 3 | Mar 10, 2026 | clinicaltrials |
| NCT02946996 | Study of Pharmacologic Manipulation of AGE (Advanced Glycation Endproducts) Levels in Prostate Cancer Patients Receiving Androgen Deprivation Therapy | terminated | Phase 2 | 41 | Medical University of South CarolinaOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT05676463 | MRI Guided Radiation Therapy for the Treatment of High Risk Prostate Cancer | terminated | Phase 2 | 6 | Thomas Jefferson UniversityOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT04754425 | Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer | terminated | Phase 2 | 11 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT05366842 | Patient-Reported Erectile Recovery and Quality of Life Outcomes With Lyopreserved Placental Tissue Applied Directly Over Neurovascular Bundle During Nerve Sparing Radical Prostatectomy Versus Standard of Care | terminated | Phase 2 | 3 | Johns Hopkins UniversityOTHER | 1 | Jan 30, 2026 | clinicaltrials |
| NCT01995058 | Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPC | terminated | Phase 2 | 54 | ExelixisINDUSTRY | 1 | Jan 8, 2026 | clinicaltrials |
| NCT04176497 | PSMA-PET/MRI Unfavorable-Risk Target Volume Pilot Study | terminated | Phase 2 | 8 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Dec 11, 2025 | clinicaltrials |
| NCT04635059 | Pacritinib for Biochemical Relapse After Definitive Treatment for Prostate Cancer(BLAST) | terminated | Phase 2 | 6 | Medical College of WisconsinOTHER | 1 | Nov 17, 2025 | clinicaltrials |
| NCT05256381 | A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors | terminated | Phase 2 | 166 | SOTIO Biotech AGINDUSTRY | 9 | Nov 17, 2025 | clinicaltrials |
| NCT05617040 | Prime-boost Immunotherapeutic Trial in Men With Biochemical Recurrence After Definitive Local Therapy for Prostate Cancer | terminated | Phase 1 / Phase 2 | 22 | Barinthus BiotherapeuticsINDUSTRY | 1 | Nov 10, 2025 | clinicaltrials |
| NCT04616547 | Treatment of Cancer-Related Bone Pain by Using Bone-Targeted Radiation-Based Therapy (Sn-117m-DTPA) in Patients With Prostate Cancer That Has Spread to Bones | terminated | Phase 2 | 1 | National Cancer Institute (NCI)NIH | 1 | Oct 3, 2025 | clinicaltrials |
| NCT04336943 | Durvalumab and Olaparib for the Treatment of Prostate Cancer in Men Predicted to Have a High Neoantigen Load | terminated | Phase 2 | 6 | University of WashingtonOTHER | 1 | Aug 11, 2025 | clinicaltrials |
| NCT03432897 | BrUOG 337: Olaparib Prior to Radical Prostatectomy For Advanced Prostate Cancer Defects in DNA Repair Genes(337) | terminated | Phase 2 | 1 | Brown UniversityOTHER | 1 | Jul 8, 2025 | clinicaltrials |
| NCT03815942 | VAccination in Early and ADvanced Prostate caNCEr(ADVANCE) | terminated | Phase 1 / Phase 2 | 23 | University of OxfordOTHER | 1 | Jun 25, 2025 | clinicaltrials |
| NCT04102124 | A Study of SHR3680 in Combination With SHR3162 in the Treatment of mCRPC | terminated | Phase 2 | 20 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jun 24, 2025 | clinicaltrials |
| NCT05712174 | A Study of [18]F-PSMA-1007 in Patients With Known or Suspected Metastatic Prostate Cancer | terminated | Phase 2 | 176 | AHS Cancer Control AlbertaOTHER | 1 | Jun 12, 2025 | clinicaltrials |
| NCT03712371 | Study of Chitosan for Pharmacologic Manipulation of AGE Levels in Prostate Cancer Patients | terminated | Phase 1 / Phase 2 | 12 | Medical University of South CarolinaOTHER | 1 | Jun 10, 2025 | clinicaltrials |
| NCT04926181 | Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prostate Cancer | terminated | Phase 2 | 2 | Rahul AggarwalOTHER | 1 | May 15, 2025 | clinicaltrials |
| NCT05177770 | Study of SRF617 With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Prostate Cancer | terminated | Phase 2 | 16 | Coherus Oncology, Inc.INDUSTRY | 2 | May 8, 2025 | clinicaltrials |
| NCT01313559 | Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate Cancer | terminated | Phase 2 | 6 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Apr 30, 2025 | clinicaltrials |
| NCT03764540 | Docetaxel Versus Cabazitaxel Post Abiraterone or Enzalutamide(CABPOSTAAT) | terminated | Phase 2 | 57 | Centre hospitalier de l'Université de Montréal (CHUM)OTHER | 1 | Apr 13, 2025 | clinicaltrials |
| NCT04556617 | PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) | terminated | Phase 1 / Phase 2 | 19 | Opna Bio LLCINDUSTRY | 2 | Apr 8, 2025 | clinicaltrials |
| NCT04383210 | Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors | terminated | Phase 2 | 54 | Elevation OncologyINDUSTRY | 4 | Apr 3, 2025 | clinicaltrials |
| NCT04382898 | PRO-MERIT (Prostate Cancer Messenger RNA Immunotherapy)(PRO-MERIT) | terminated | Phase 1 / Phase 2 | 75 | BioNTech SEINDUSTRY | 4 | Mar 20, 2025 | clinicaltrials |
| NCT04298983 | Abemaciclib in Combination With Androgen Deprivation Therapy for Locally Advanced Prostate Cancer(RAD 1805) | terminated | Phase 2 | 9 | University of Alabama at BirminghamOTHER | 1 | Mar 19, 2025 | clinicaltrials |
| NCT06257758 | A Phase 1/2 Study of VIO-01 in Participants With Recurrent Solid Tumors | terminated | Phase 1 / Phase 2 | 6 | Valerio TherapeuticsINDUSTRY | 1 | Mar 17, 2025 | clinicaltrials |
Data updated 22 days agoSource updated Aug 26, 2026source: clinicaltrials